A newly developed personalized scoring index computed based on the expression levels of PPARγ target genes applied to merged microarray data (MMD) consisting exclusively of thyroid cancers and normal tissues and TCGA-THCA (thyroid carcinoma) data revealed its robust diagnostic and prognostic ability in predicting tissue-based disease-specific survival (DSS). This evidence concerns the gene PPARG and thyroid gland carcinoma.